Zacks Investment Research lowered shares of Compugen Ltd. (NASDAQ:CGEN) from a hold rating to a sell rating in a research note published on Friday, August 4th.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, FBR & Co set a $14.00 price objective on shares of Compugen and gave the stock a buy rating in a research report on Friday, May 19th.
Compugen (NASDAQ CGEN) traded up 1.56% on Friday, reaching $3.25. 87,932 shares of the company’s stock were exchanged. Compugen has a 1-year low of $3.10 and a 1-year high of $7.57. The company’s market capitalization is $166.18 million. The firm has a 50-day moving average price of $3.64 and a 200-day moving average price of $4.14.
Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.01. Compugen had a negative return on equity of 57.69% and a negative net margin of 4,425.00%. Equities research analysts expect that Compugen will post ($0.73) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/08/18/zacks-investment-research-downgrades-compugen-ltd-nasdaqcgen-to-sell-updated.html.
Several institutional investors have recently made changes to their positions in CGEN. Renaissance Technologies LLC increased its position in shares of Compugen by 15.6% in the fourth quarter. Renaissance Technologies LLC now owns 534,900 shares of the biotechnology company’s stock worth $2,728,000 after buying an additional 72,075 shares in the last quarter. Norges Bank bought a new position in shares of Compugen during the fourth quarter worth about $658,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Compugen by 5.7% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 66,300 shares of the biotechnology company’s stock worth $285,000 after buying an additional 3,600 shares in the last quarter. Vident Investment Advisory LLC increased its position in shares of Compugen by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 150,614 shares of the biotechnology company’s stock worth $648,000 after buying an additional 25,100 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Compugen by 9.4% in the first quarter. Morgan Stanley now owns 813,200 shares of the biotechnology company’s stock worth $3,497,000 after buying an additional 69,754 shares in the last quarter. Institutional investors and hedge funds own 19.37% of the company’s stock.
About Compugen
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
